Source comparison
Comparison: Sermorelin Study Designs by Research Objective
IGF-1 Response Trial Serum IGF-1 elevation 12–16 weeks Blood draw at baseline, 4, 8, 12 weeks Adults with baseline IGF-1 <150ng/mL Demonstrates pituitary responsiveness; most reproducible endpoint for peptide quality verification Body Composition Study Lean ma
This comparison does not assign a generated winner or score.
- IGF-1 Response Trial
- Serum IGF-1 elevation
- 12–16 weeks
- Blood draw at baseline, 4, 8, 12 weeks
- Adults with baseline IGF-1 <150ng/mL
- Demonstrates pituitary responsiveness; most reproducible endpoint for peptide quality verification
- Body Composition Study
- Lean mass gain, fat loss
- 16–24 weeks
- DEXA scan, CT scan for visceral fat
- Middle-aged adults with sarcopenia or metabolic syndrome
- Shows downstream metabolic effects; requires longer timelines to detect significant changes
- Safety & Tolerability Protocol
- Adverse event rates, cardiovascular markers
- 24–48 weeks
- Injection site monitoring, ECG, echocardiography, lipid panels
- Healthy adults or those with GH deficiency
- Establishes long-term safety profile; critical for regulatory documentation
- Sleep & Recovery Study
- Sleep architecture, subjective recovery scores
- 8–12 weeks
- Polysomnography, sleep questionnaires
- Athletes or shift workers with disrupted sleep
- Explores non-body composition benefits; less standardized methodology